Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer

Cervical cancer is a serious threat to women's health globally. Therefore, identifying key molecules associated with cervical cancer progression is essential for drug development, disease monitoring, and precision therapy. Recently, TGF-beta (transforming growth factor-beta) has been identified as a promising target for cervical cancer treatment. For advanced cervical cancer, TGF-beta participates in tumor development by improving metastasis, stemness, drug resistance, and immune evasion. Accumulating evidence demonstrates that TGF-beta blockade effectively improves the therapeutic effects, especially immunotherapy. Currently, agents targeting TGF-beta and immune checkpoints such as PD-L1 have been developed and tested in clinical studies. These bispecific antibodies might have the potential as therapeutic agents for cervical cancer treatment in the future.

Automated summary

Cervical cancer is a serious global threat to women's health, and identifying key molecules associated with its progression is crucial for drug development, disease monitoring, and precision therapy. TGF-beta has recently emerged as a promising target for cervical cancer treatment, particularly in the field of immunotherapy.